论文部分内容阅读
为了解新一代国产乳酸左氧氟沙星注射液治疗成人下呼吸道感染的疗效及安全性,我们将90例患者随机分成两组,分别给予乳酸左氧氟沙星400m g/d 或头孢呋辛钠3.0g/d 治疗,疗程7～14d。结果显示:乳酸左氧氟沙星治疗痊愈率66.7% ,有效率93.3% ,细菌清除率93.3% ,其临床疗效均高于头孢呋辛钠组,但差别无显著性(P> 0.05);乳酸左氧氟沙星不良反应发生率为4.4% ,且大多轻微,患者可耐受。结论:对中重度下呼吸道感染患者,特别是病原菌尚未确定的病人,给予乳酸左氧氟沙星治疗是有效且安全的首选方案,具有较高的临床应用价值
To understand the efficacy and safety of a new generation of homemade levofloxacin lactate injection for the treatment of adult lower respiratory tract infection, 90 patients were randomly divided into two groups, respectively, levofloxacin lactate 400m g / d or cefuroxime sodium 3.0g / d treatment, treatment 7 ~ 14d. The results showed that the cure rate of levofloxacin lactate was 66.7%, the effective rate was 93.3% and the bacterial clearance rate was 93.3%. The clinical efficacy of levofloxacin lactate was higher than that of cefuroxime sodium group, but the difference was not significant (P> 0.05). The levofloxacin lactate adverse reaction Rate of 4.4%, and most minor, patients can tolerate. Conclusion: Levofloxacin lactate is an effective and safe first choice for patients with moderate-severe lower respiratory tract infection, especially for patients whose pathogens have not been determined, which has high clinical value